Aurora Cannabis Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Aurora Cannabis wird ein jährliches Gewinn- und Umsatzwachstum von 70.7% bzw. 13.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 71.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.8% betragen.

Wichtige Informationen

79.2%

Wachstumsrate der Gewinne

79.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	74.8%
Wachstumsrate der Einnahmen	12.1%
Zukünftige Eigenkapitalrendite	-1.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	27 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump

Jun 27

Downgrade: Here's How Analysts See Aurora Cannabis Inc. (TSE:ACB) Performing In The Near Term

Nov 13

Does Aurora Cannabis (TSE:ACB) Have A Healthy Balance Sheet?

Sep 22

Aurora Cannabis (TSE:ACB) Is Carrying A Fair Bit Of Debt

Apr 21

Is Aurora Cannabis (TSE:ACB) Using Too Much Debt?

Jan 05

A Look At The Intrinsic Value Of Aurora Cannabis Inc. (TSE:ACB)

Nov 13

Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?

Oct 04

Gewinn- und Umsatzwachstumsprognosen

TSX:ACB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	373	-6	N/A	N/A	2
3/31/2026	342	-5	17	30	5
3/31/2025	301	-22	-26	-25	6
3/31/2024	270	-55	-85	-69	N/A
12/31/2023	276	411	-99	-83	N/A
9/30/2023	273	374	-153	-139	N/A
6/30/2023	258	331	-149	-139	N/A
3/31/2023	224	-793	-163	-142	N/A
12/31/2022	212	-1,748	-181	-157	N/A
9/30/2022	210	-1,757	-152	-118	N/A
6/30/2022	221	-1,718	-142	-110	N/A
3/31/2022	226	-1,233	-98	-64	N/A
12/31/2021	231	-381	-122	-82	N/A
9/30/2021	238	-607	-165	-124	N/A
6/30/2021	245	-692	-264	-211	N/A
3/31/2021	257	-2,387	-357	-284	N/A
12/31/2020	275	-2,359	-430	-285	N/A
9/30/2020	263	-3,342	-614	-357	N/A
6/30/2020	269	-3,231	-691	-342	N/A
3/31/2020	299	-1,405	-778	-293	N/A
12/31/2019	291	-1,430	-787	-289	N/A
9/30/2019	290	-385	-667	-218	N/A
6/30/2019	246	-294	-606	-192	N/A
3/31/2019	168	-211	-519	-233	N/A
12/31/2018	119	-72	-439	-206	N/A
9/30/2018	77	174	-334	-146	N/A
6/30/2018	55	72	-219	-82	N/A
3/31/2018	42	-13	-146	-35	N/A
12/31/2017	31	7	N/A	-16	N/A
9/30/2017	23	-4	N/A	-15	N/A
6/30/2017	18	-13	N/A	-13	N/A
3/31/2017	13	-16	N/A	-17	N/A
12/31/2016	8	-13	N/A	-11	N/A
9/30/2016	5	-10	N/A	-9	N/A
6/30/2016	1	-6	N/A	-7	N/A
3/31/2016	0	0	N/A	-5	N/A
12/31/2015	N/A	-3	N/A	-3	N/A
9/30/2015	N/A	-10	N/A	-3	N/A
6/30/2015	N/A	-10	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ACB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ACB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ACBDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (7.3% pro Jahr).

Hohe Wachstumseinnahmen: ACBDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ACB wird voraussichtlich in 3 Jahren unrentabel sein.

Aurora Cannabis Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 13% to CA$8.43

Consensus EPS estimates fall by 550%

Forecast breakeven date pushed back to 2027

Consensus EPS estimates upgraded to CA$1.44 loss

Price target increased by 62% to CA$16.58

Consensus EPS estimates fall by 48%, revenue upgraded

Recent updates

Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump

Price target decreased by 13% to CA$8.43

Consensus EPS estimates fall by 550%

Full year 2024 earnings released: CA$1.28 loss per share (vs CA$8.22 loss in FY 2023)

Forecast breakeven date pushed back to 2027

Aurora Cannabis Inc. Appoints Rajesh Uttamchandani to its Board of Directors

Aurora Cannabis Inc. in Conjunction with MedReleaf Australia, Announce Expansion of its Portfolio with Introduction of New Range of Premium Dried Cannabis Flower Products

New minor risk - Share price stability

Consensus EPS estimates upgraded to CA$1.44 loss

Price target increased by 62% to CA$16.58

Aurora Cannabis Inc. Announces CFO Changes

Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

New minor risk - Profitability

Consensus EPS estimates fall by 48%, revenue upgraded

Aurora Cannabis Inc. (TSX:ACB) acquired remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million.

Aurora Cannabis Inc. Provides Earnings Guidance for the Fourth Quarter of Fiscal 2024

Aurora Cannabis Inc. to Report Q3, 2024 Results on Feb 08, 2024

Forecast to breakeven in 2026

New major risk - Financial position

Aurora Cannabis Inc. Provides Revenue Guidance for Third Quarter of Fiscal 2024

Aurora Cannabis Inc. to Report Q2, 2024 Results on Nov 09, 2023

New major risk - Shareholder dilution

Insider exercised options and sold CA$62k worth of stock

Aurora Cannabis Inc. has completed a Follow-on Equity Offering in the amount of CAD 38.826875 million.

Is Aurora Cannabis (TSE:ACB) Using Too Much Debt?

Price target decreased by 27% to CA$0.96

New major risk - Financial position

Aurora Cannabis Inc. Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024

Aurora Cannabis Inc. to Report Q1, 2024 Results on Aug 10, 2023

Bevo Farms Ltd acquired Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) for CAD 15 million.

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

CEO & Director recently bought CA$131k worth of stock

New minor risk - Profitability

Consensus EPS estimates upgraded to CA$0.16 loss, revenue downgraded

Price target decreased by 20% to CA$1.49

Price target decreased by 10% to CA$1.75

Investors Holding Back On Aurora Cannabis Inc. (TSE:ACB)

Aurora Cannabis Inc. to Report Fiscal Year 2023 Results on Jun 14, 2023

Aurora Celebrates Summer with New Innovation Launching Across Canada

Aurora Cannabis Inc., Annual General Meeting, Aug 14, 2023

Forecast to breakeven in 2026

Aurora Cannabis Inc. Reports Impairment Changes for the Quarter Ended December 31, 2022

Price target decreased by 10% to CA$2.05

Second quarter 2023 earnings released

Aurora Cannabis Inc. to Report Q2, 2023 Results on Feb 09, 2023

Is Aurora Cannabis (TSE:ACB) Using Debt Sensibly?

An Unknown buyer acquired Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million.

Now 22% undervalued after recent price drop

Consensus revenue estimates fall by 14%

Forecast to breakeven in 2025

Downgrade: Here's How Analysts See Aurora Cannabis Inc. (TSE:ACB) Performing In The Near Term

First quarter 2023 earnings released: CA$0.17 loss per share (vs CA$0.06 loss in 1Q 2022)

Aurora Cannabis Inc. to Report Q1, 2023 Results on Nov 10, 2022

Aurora Announces Unprecedented Fall Product Release Across Adult-Use and Medical Markets

Aurora Announces Unprecedented Fall Product Release Across Adult-Use and Medical Markets

Consensus forecasts updated

Does Aurora Cannabis (TSE:ACB) Have A Healthy Balance Sheet?

Full year 2022 earnings: Revenues in line with analyst expectations

Price target decreased to CA$3.07

Aurora Cannabis Inc. to Report Q4, 2022 Results on Sep 20, 2022

Aurora Cannabis Inc., Annual General Meeting, Nov 14, 2022

Aurora Cannabis Inc. (TSX:ACB) acquired 50.1% stake in Bevo Agtech Inc. for CAD 57 million.

Independent Director recently bought CA$84k worth of stock

Aurora Cannabis Inc. has completed a Composite Units Offering in the amount of $150.00125 million.

Aurora Cannabis Inc. has completed a Composite Units Offering in the amount of $125.195 million.

Consensus EPS estimates fall by 397%